Feature

The drug push

+ See all authors and affiliations

Science  22 May 2015:
Vol. 348, Issue 6237, pp. 850-853
DOI: 10.1126/science.348.6237.850

You are currently viewing the summary.

View Full Text

Summary

Antibiotics face an unfortunate paradox: Though we desperately need new drugs to combat the growing threat of resistant bacteria, their discovery and development has ground to a crawl. A series of financial, scientific, and regulatory setbacks have driven companies out of the field, and many of the investors who could help get new drug candidates to the clinic are skeptical that such drugs can be profitable. Now, some are heralding new signs of life, including the return of a few pharmaceutical superpowers. But will desperate moves by governments to entice companies and researchers be enough to spring the next generation of antibiotics from the lab?

Related Content